Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mani

Showing results (141-150 of 169) with videos related to

Pageof 17
Sort By:
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|November 16, 2016
Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypesSamir R Shah, P N Rao, Shiv K Sarin, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.
Journal of Hepatology|October 7, 2018
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertibSaumya Jayakumar, Michael S Middleton, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsQuentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 23, 2018
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV InfectionWai-Kay Seto, Yasuhiro Asahina, Todd T Brown, et al.
Hepatology (Baltimore, Md.)|March 3, 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled TrialKeyur Patel, Stephen A Harrison, Magdy Elkhashab, et al.
Pageof 17

Showing results (141-150 of 169) with videos related to

Sort By:
Pageof 17
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|November 16, 2016
Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypesSamir R Shah, P N Rao, Shiv K Sarin, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.
Journal of Hepatology|October 7, 2018
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertibSaumya Jayakumar, Michael S Middleton, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsQuentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 23, 2018
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV InfectionWai-Kay Seto, Yasuhiro Asahina, Todd T Brown, et al.
Hepatology (Baltimore, Md.)|March 3, 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled TrialKeyur Patel, Stephen A Harrison, Magdy Elkhashab, et al.
Pageof 17